CEO SUMMARY: In the midst of expanding their toxicology testing services nationally, DrugScan and DSI Medical Services (collectively Toxicology Holdings Inc.) hired a brokerage firm last year to pursue a sale of the two toxicology companies. Multiple potential buyers responded with interest. The buyer, ACM Global Laboratories—owned by a health system in Rochester, N.Y.—saw the
Tag: clinical trials
CEO SUMMARY: It is unusual when a regional health system’s clinical lab company acquires a commercial lab company outside its geographic home. But that’s what happened in December when Rochester Regional Health System’s subsidiary, ACM Global Laboratories, acquired a toxicology testing lab and a pre-employment drug-screening company, both in Horsham, Pa., more than 300 miles
In a development that has implications for medical laboratories in developed nations, healthcare organizations in Africa have launched a “landmark electronic referral project” to digitally track workers who travel to South Africa to work in the mining industry. The project is being administered by TIMS (TB in the Mining Sector in South Africa). This digital medical
CEO SUMMARY: In more than 40 presentations by 55 speakers, two big themes dominated the 11th annual Lab Quality Confab in New Orleans last week. One theme is the urgent need to cut clinical laboratory costs. The second theme is the need for both clinical labs and anatomic pathology groups to deliver more value to
FOR THE PAST SEVERAL YEARS, and particularly since Congress passed the Patient Access to Medicare Act in 2014, clinical labs have focused on controlling costs, as they should. After all, PAMA calls for steep cuts in what the federal Centers for Medicare and Medicaid Services will pay clinical labs beginning Jan. 1, 2018. (See TDRs,
HEALTHCARE BIG DATA IS ADVANCING in California and all pathologists in the Golden State will be required to submit data to the state’s cancer registry beginning in 2019.
California’s new law to support the state’s cancer registry is the latest example of an effort to ensure the timely collection of complete sets of data needed to
CEO SUMMARY: Across the nation, pathologists are at a crossroads. Now that the FDA has cleared a digital pathology and whole slide imaging (WSI) system for use in primary diagnosis, should they adopt this technology sooner or wait until later? One pathologist who has worked with WSI for many years shared the lessons learned in
CEO SUMMARY: Moving away from volume-based care will not be easy for clinical labs. After all, high volume sustains labs. But labs seeking to transition away from fee-for-service to value-based care must have a seat at the table where decisions are made, said a lab CEO who is part of Project Santa Fe, which wants
IN RECENT WEEKS, the nation’s two largest lab companies reported fourth quarter and full-year earnings for 2015. The earnings reports reveal how the paths of the two companies are diverging.
The companies are diverging because of a major acquisition made in February 2015, by Laboratory Corporation of America. LabCorp bought Covance Inc. in a deal valued at
CEO SUMMARY: Forty years ago, pathologists in hospital and academic labs worked closely with treating physicians to produce laboratory-developed tests for discrete clinical cases. Seeing that, the FDA decided not to regulate those tests, an FDA official said. Over time, however, use of LDTs became a serious concern when labs developing LDTs were no longer involved